Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
Artivion, Inc. (NYSE: AORT) is a medical device company focused on cardiac and vascular surgery, particularly the treatment of aortic diseases. News about Artivion frequently centers on its aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as clinical and regulatory developments related to these products.
Investors and clinicians following AORT news can expect regular updates on quarterly financial results, including revenue trends for key product lines such as stent grafts, On-X valves, BioGlue surgical sealant and preservation services. Earnings releases often discuss constant currency growth, adjusted EBITDA and non-GAAP performance metrics, along with management’s commentary on business momentum and financial outlook.
Artivion’s news flow also highlights progress in its aortic disease clinical programs. Recent announcements have covered the PERSEVERE and PROTECT trials for the AMDS Hybrid Prosthesis, including late-breaking data presented at major cardiothoracic surgery meetings, as well as the ARTIZEN pivotal trial evaluating the Arcevo LSA Hybrid Stent Graft System for acute and chronic aortic arch pathologies. These updates provide insight into the clinical performance and potential regulatory pathways for the company’s aortic technologies.
Additional news items may include participation in healthcare and medtech investor conferences, amendments to credit facilities, real estate transactions related to manufacturing capacity, and executive leadership changes disclosed through SEC filings and press releases. For market participants tracking AORT, this news page offers a centralized view of Artivion’s financial communications, clinical milestones and corporate developments over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Artivion, Inc. (NYSE: AORT), a leader in cardiac and vascular surgery solutions, announced that it will release its first quarter 2023 financial results on May 4, 2023, post-market. A teleconference call and live webcast will follow at 4:30 p.m. ET, hosted by Chairman and CEO Pat Mackin. Investors can access the teleconference by dialing 862-298-0702. The replay will be available within an hour post-event. This announcement emphasizes Artivion's ongoing commitment to transparency with its stakeholders regarding its financial performance. The company's innovative product lines, including aortic stent grafts and surgical sealants, aim to address complex cardiac challenges, positioning Artivion within the competitive landscape of over 100 countries globally.
Artivion, Inc. (NYSE: AORT) announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, scheduled for April 18, 2023 at 8:45 a.m. ET. The company's virtual fireside chat will focus on advancements in cardiac and vascular surgery for aortic diseases.
A live webcast will be available on Artivion's website, with an archived version accessible for 90 days. Headquartered in Atlanta, Georgia, Artivion specializes in solutions for cardiac and vascular surgeons, offering products such as aortic stents, surgical sealants, On-X mechanical heart valves, and implantable human tissues, distributed in over 100 countries.
Artivion, Inc. (NYSE: AORT), a leader in cardiac and vascular surgery, announced its participation in the Oppenheimer 33rd Annual Healthcare Conference. The virtual event is set for March 14, 2023, at 3:20 p.m. ET. A live webcast will be available on Artivion's website, with a 90-day archive post-event. Headquartered in Atlanta, Georgia, Artivion specializes in solutions for aortic disease, offering products like aortic stents, surgical sealants, and On-X mechanical heart valves. The company operates in over 100 countries globally. For more information, visit www.artivion.com.
Artivion, Inc. (NYSE: AORT) reported its fourth quarter and full-year 2022 results. The fourth quarter revenues were $79.4 million, flat year-over-year, but up 5% on a non-GAAP constant currency basis. For the full year, revenues reached $313.8 million, a 5% increase on a GAAP basis. Net income for Q4 2022 was $2.2 million compared to a net loss of $20.1 million in Q4 2021. The company anticipates 2023 revenue growth of 8.0% to 12%, with projected revenues between $331 million and $343 million. A CE mark for BioGlue was received, and confidence was noted for PMA approval for PerClot.
Artivion, Inc. (NYSE: AORT) announced its fourth-quarter and full-year 2022 financial results will be released on February 16, 2023, post-market. The Company will host a teleconference at 4:30 p.m. ET to discuss these results, followed by a Q&A session led by Pat Mackin, Chairman and CEO. Interested parties can listen live by dialing 201-689-8261 or access the webcast through the Artivion website. A replay will be available shortly after the call. Artivion specializes in medical devices for aortic diseases, offering products in over 100 countries.